Medtronic (NYSE:MDT) Price Target Cut to $115.00 by Analysts at Argus

Medtronic (NYSE:MDT) had its target price trimmed by Argus from $125.00 to $115.00 in a research report sent to investors on Monday morning, Marketbeat.com reports. The firm currently has a buy rating on the medical technology company’s stock.

MDT has been the topic of several other reports. Piper Sandler dropped their price target on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Citigroup initiated coverage on shares of Medtronic in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price target on the stock. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Finally, UBS Group reiterated a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $109.85.

Medtronic Stock Down 0.4%

MDT stock opened at $86.27 on Monday. The firm has a market capitalization of $110.77 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 2.24 and a beta of 0.75. Medtronic has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The company’s 50 day moving average price is $94.18 and its 200 day moving average price is $96.19.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts anticipate that Medtronic will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio is presently 79.11%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.26% of the company’s stock.

Institutional Investors Weigh In On Medtronic

Large investors have recently modified their holdings of the company. Monetary Solutions Ltd acquired a new stake in shares of Medtronic in the fourth quarter valued at approximately $27,000. Corundum Trust Company INC acquired a new stake in shares of Medtronic during the third quarter worth $27,000. Lodestone Wealth Management LLC acquired a new stake in shares of Medtronic during the fourth quarter worth $27,000. Anfield Capital Management LLC lifted its holdings in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares during the period. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Medtronic during the fourth quarter worth $29,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).